Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept.
Platelet-to-lymphocyte ratio
aflibercept
metastatic colorectal cancer
predictive marker
prognosis
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
10
04
2020
revised:
24
04
2020
accepted:
29
04
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
The efficacy of aflibercept plus 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) therapy has been demonstrated in patients with metastatic colorectal cancer (mCRC) in global and Japanese clinical trials. However, a practical biomarker to predict its efficacy is lacking. This was a single-institution retrospective study of 21 patients with mCRC consecutively treated with aflibercept plus FOLFIRI from March 2018 to July 2019. We investigated the association and predictive value of pretreatment blood inflammation and immune-based scores, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio, using their median values as cut-offs, in regard to disease control (DC), progression-free (PFS), and overall (OS) survival. The number of patients in each treatment line of aflibercept was as follows: Second, 14 (66.7%); third, four (19.0%); fourth, two (9.5%); eighth, one (4.8%). The median number of aflibercept treatment courses was seven (range=2-17). The median follow-up time was 391 days. In univariate analysis, patients with DC had a significantly lower PLR than those without DC. Only the PLR was significantly negatively associated with PFS, but not with OS. Multivariate analysis showed a significantly poor prognostic impact of a high PLR on PFS (hazard ratio=10.28; p=0.003). A low pretreatment PLR might be a predictor of aflibercept efficacy in patients with mCRC and may be clinically useful for selecting patient responders.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The efficacy of aflibercept plus 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) therapy has been demonstrated in patients with metastatic colorectal cancer (mCRC) in global and Japanese clinical trials. However, a practical biomarker to predict its efficacy is lacking.
PATIENTS AND METHODS
METHODS
This was a single-institution retrospective study of 21 patients with mCRC consecutively treated with aflibercept plus FOLFIRI from March 2018 to July 2019. We investigated the association and predictive value of pretreatment blood inflammation and immune-based scores, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio, using their median values as cut-offs, in regard to disease control (DC), progression-free (PFS), and overall (OS) survival.
RESULTS
RESULTS
The number of patients in each treatment line of aflibercept was as follows: Second, 14 (66.7%); third, four (19.0%); fourth, two (9.5%); eighth, one (4.8%). The median number of aflibercept treatment courses was seven (range=2-17). The median follow-up time was 391 days. In univariate analysis, patients with DC had a significantly lower PLR than those without DC. Only the PLR was significantly negatively associated with PFS, but not with OS. Multivariate analysis showed a significantly poor prognostic impact of a high PLR on PFS (hazard ratio=10.28; p=0.003).
CONCLUSION
CONCLUSIONS
A low pretreatment PLR might be a predictor of aflibercept efficacy in patients with mCRC and may be clinically useful for selecting patient responders.
Identifiants
pubmed: 32871798
pii: 34/5/2667
doi: 10.21873/invivo.12086
pmc: PMC7652534
doi:
Substances chimiques
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2667-2673Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
PLoS One. 2014 Nov 03;9(11):e111839
pubmed: 25365378
Cancer Sci. 2019 Mar;110(3):1032-1043
pubmed: 30657223
Ann Surg Oncol. 2002 Apr;9(3):287-91
pubmed: 11923136
F1000Res. 2014 Jul 31;3:180
pubmed: 25469228
Int J Clin Oncol. 2020 Jan;25(1):1-42
pubmed: 31203527
Am J Kidney Dis. 1999 May;33(5):1004-10
pubmed: 10213663
Anticancer Res. 2019 Aug;39(8):4343-4350
pubmed: 31366528
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
J Nippon Med Sch. 2019;86(3):142-148
pubmed: 31292325
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancer Treat Rev. 2012 Aug;38(5):484-93
pubmed: 22264850
Br J Cancer. 2015 Sep 29;113(7):1027-34
pubmed: 26355232
Dig Surg. 2015;32(6):496-503
pubmed: 26544755
FEBS Open Bio. 2016 Jun 16;6(7):742-50
pubmed: 27398314
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Sci. 2019 Nov;110(11):3565-3572
pubmed: 31520559
Sci Rep. 2017 Dec 7;7(1):17166
pubmed: 29215037
Ann Surg Oncol. 2016 Feb;23(2):646-54
pubmed: 26416715
Thromb Res. 2018 Apr;164 Suppl 1:S148-S152
pubmed: 29703474
Cancer Med. 2019 Mar;8(3):882-889
pubmed: 30690930
Clin Colorectal Cancer. 2020 Mar;19(1):39-47.e5
pubmed: 31648924
World J Gastrointest Oncol. 2014 Feb 15;6(2):34-40
pubmed: 24567794
Exp Eye Res. 2018 Oct;175:166-172
pubmed: 29908884
Int J Clin Oncol. 2020 Apr;25(4):633-640
pubmed: 31781993
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878